Rajashree Panigrahi

Rajashree Panigrahi

Auto-generated profile, based on publicly available information

Rajashree Panigrahi

Department of Microbiology, IMS and SUM Hospital, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
BYBeema T Yoosuf
Beema T Yoosuf
AGAbhay Gaidhane
Abhay Gaidhane
NVNasir Vadia
Nasir Vadia
SMSoumya V. Menon
Soumya V. Menon
KCKattela Chennakesavulu
Kattela Chennakesavulu
DJDiptismita Jena
Diptismita Jena

4 June 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
MKMunthar Kedhim
Munthar Kedhim
VJVicky Jain
Vicky Jain
SBSuhas Ballal
Suhas Ballal
AKAbhinav Kumar
Abhinav Kumar
ASAbhayveer Singh
Abhayveer Singh
HNHadi Noorizadeh
Hadi Noorizadeh
Dual-mode dopamine sensor using CsPbBr3-PQD-COF nanocomposites achieves femtosecond sensitivity (0.3 fM fluorescence, 2.5 fM EIS) with visual readout and high specificity for biomedical applications.

3 July 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
AEAbdelgawwad El-Sehrawy
Abdelgawwad El-Sehrawy
AMAmr Ali Mohamed
Amr Ali Mohamed
AAAbdulla A. Al-Dulaimi
Abdulla A. Al-Dulaimi
AAAli Gaithan Alkhathami
Ali Gaithan Alkhathami
RSRenuka Jyothi S
Renuka Jyothi S
MAMohammed Jawad Alnajar
Mohammed Jawad Alnajar

12 February 2025 in European Journal of Translational Myology
Verified
Journal Article
Open access
PDF file
AEAmr Ali Mohamed Abdelgawwad El-Sehrawy
Amr Ali Mohamed Abdelgawwad El-Sehrawy
IAIbtihal Ibrahim Ayoub
Ibtihal Ibrahim Ayoub
Subasini - UthirapathySubasini - Uthirapathy
Subasini - Uthirapathy
SBSuhas Ballal
Suhas Ballal
BGBaneen C. Gabble
Baneen C. Gabble
MKMohsen Khosravi
Mohsen Khosravi
The intricate relationship between gut microbiota and the brain has emerged as a pivotal area of research, particularly in understanding myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This complex condition is characterized by debilitating fatigue, cognitive dysfunction, and a wide array of systemic manifestations, posing significant challenges for diagnosis and treatment. Recent studies highlight the microbiota-gut-brain axis as a crucial pathway in ME/CFS pathophysiology, suggesting that alterations in gut microbial composition may impact immune responses, neurochemical signaling, and neuronal health. This narrative review systematically explores English-language scholarly articles from January 1995 to January 2025, utilizing databases such as PubMed, Scopus, and Web of Science. The findings underscore the potential for targeted therapeutic interventions aimed at correcting gut dysbiosis. As research progresses, a deeper understanding of the microbiota-gut-brain connection could lead to innovative approaches for managing ME/CFS, ultimately enhancing the quality of life for affected individuals.

13 July 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
BLBingru Li
Bingru Li
OAOmer Qutaiba B. Allela
Omer Qutaiba B. Allela
WAWadhah Hasan Alkhazali
Wadhah Hasan Alkhazali
NVNasir Vadia
Nasir Vadia
SJS. Renuka Jyothi
S. Renuka Jyothi
MAMohaned Adil
Mohaned Adil

26 November 2025 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
PSPrakasini Satapathy
Prakasini Satapathy
AGAbhay Gaidhane
Abhay Gaidhane
NVNasir Vadia
Nasir Vadia
SMSoumya V. Menon
Soumya V. Menon
KCKattela Chennakesavulu
Kattela Chennakesavulu
Ganesh BushiGanesh Bushi
Ganesh Bushi
Objective Polypharmacy, the concurrent use of five or more medications, is prevalent among older adults with Diabetes, a population at elevated risk for medication-related complications. Complex treatment regimens for Diabetes and its comorbidities exacerbate challenges such as medication non-adherence, drug interactions, adverse events, and increased hospitalization risk. This review aimed to estimate the prevalence of polypharmacy among older adults with Diabetes. Method Following PRISMA 2020 guidelines, we performed a systematic search of PubMed, Embase, and Web of Science. Screened articles using Nested Knowledge software. Eligible studies included those aged 60 years or older with Diabetes, reporting on the prevalence of polypharmacy. Study quality was assessed using a modified Newcastle-Ottawa Scale, and meta-analysis was performed using random-effects models in R software version 4.4.1. Publication bias was indicated by a Doi plot with an LFK index. Results The pooled prevalence of polypharmacy was 59% (95% CI, 48%-70%). Subgroup analyses showed a prevalence of 55% in retrospective studies and 62% in cross-sectional studies. Sensitivity analyses confirmed the stability of the results. Significant geographic variability was noted, with lower prevalence in high-income countries compared to regions in Southern Europe and Asia. Conclusions Polypharmacy is highly prevalent among older adults with Diabetes, with significant variability across study designs and geographic regions. Targeted interventions and further research are essential to address its associated risks and optimize medication management.